About alaunos therapeutics inc - TCRT
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.
TCRT At a Glance
Alaunos Therapeutics, Inc.
501 East Las Olas Boulevard
Fort Lauderdale, Florida 33301
| Phone | 1-346-355-4099 | Revenue | 5.00K | |
| Industry | Biotechnology | Net Income | -4,176,000.00 | |
| Sector | Health Technology | Employees | 1 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TCRT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1,258.639 |
| Price to Book Ratio | 3.525 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.164 |
| Enterprise Value to Sales | 981.639 |
| Total Debt to Enterprise Value | N/A |
TCRT Efficiency
| Revenue/Employee | 5,000.00 |
| Income Per Employee | -4,176,000.00 |
| Receivables Turnover | 1.667 |
| Total Asset Turnover | 0.002 |
TCRT Liquidity
| Current Ratio | 2.445 |
| Quick Ratio | 2.445 |
| Cash Ratio | 1.704 |
TCRT Profitability
| Gross Margin | -40.00 |
| Operating Margin | -84,500.00 |
| Pretax Margin | -83,520.00 |
| Net Margin | -83,520.00 |
| Return on Assets | -145.988 |
| Return on Equity | -198.102 |
| Return on Total Capital | -193.962 |
| Return on Invested Capital | -198.102 |
TCRT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |